Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline

Area of Science:

• Nephrology
• Hepatology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection poses a significant global health burden, frequently co-occurring with chronic kidney disease (CKD).
• Prevalence of HCV is notably higher in CKD populations, including hemodialysis patients and kidney transplant recipients, compared to the general population.
• The management landscape for HCV in CKD has evolved significantly, marked by updated guidelines from Kidney Disease: Improving Global Outcome (KDIGO).

Purpose of the Study:

• To provide a synopsis of the updated KDIGO 2018 guideline for hepatitis C in CKD.
• To focus on the clinical application of direct-acting antivirals (DAAs) in advanced CKD, dialysis patients, and transplant recipients.
• To highlight key considerations for HCV management in CKD, including screening, treatment, prevention, and drug interactions.

Main Methods:

• Narrative review of the KDIGO 2018 guideline for hepatitis C in CKD.
• Focus on clinical aspects of direct-acting antivirals (DAAs) in specific CKD populations.
• Discussion of drug-drug interactions and treatment timing relative to kidney transplantation.

Main Results:

• Updated recommendations cover screening, detection, and treatment of HCV in CKD patients.
• Guidance is provided for HCV treatment before and after kidney transplantation.
• Emphasis on managing drug-drug interactions between DAAs and immunosuppressants is crucial.

Conclusions:

• The 2018 KDIGO guideline offers comprehensive strategies for managing HCV in CKD patients.
• DAAs are effective in advanced CKD, dialysis, and transplant populations, requiring careful drug interaction management.
• Further research is needed to address remaining uncertainties in HCV management within the CKD spectrum.